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protein (CETP) inhibitor currently under
investigation to reduce cardiovascular
events in patients with high risk vascular
disease.
• The patient population expected to take
which are predominately metabolized by
cytochrome P450 (CYP)-3A.
affect the safety and/or efﬁcacy of other
drugs taken by this patient population.
WHAT THIS STUDY ADDS
• A clinical study with probe substrates
selected by in vitro risk assessment and
modelling approaches suggests no
evidence of clinically relevant DDI with
evacetrapib as the perpetrator drug.
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statin, suggesting that dose adjustments to
this medication will not be warranted.
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7 August 2015• Evacetrapib is a cholesteryl ester-transfer
AIMS
Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor under
development for reducing cardiovascular events in patients with high
risk vascular disease. CETP inhibitors are likely to be utilized as ‘add-on’
therapy to statins in patients receiving concomitant medications, so
the potential for evacetrapib to cause clinically important drug–drug
interactions (DDIs) with cytochromes P450 (CYP) was evaluated.CETP inhibitors is likely to be taking multiple
concomitant medications, including statins, METHODS
The DDI potential of evacetrapib was investigated in vitro, followed
by predictions to determine clinical relevance. Potential DDIs with
possible clinical implications were then investigated in the clinic.• Clinically relevant drug–drug interactions
(DDIs) with evacetrapib could potentially RESULTS
In vitro, evacetrapib inhibited all of the major CYPs, with inhibition
constants (Ki) ranging from 0.57 μM (CYP2C9) to 7.6 μM (CYP2C19).
Evacetrapib was a time-dependent inhibitor and inducer of CYP3A. The
effects of evacetrapib on CYP3A and CYP2C9 were assessed in a phase
1 study using midazolam and tolbutamide as probe substrates,
respectively. After 14 days of daily dosing with evacetrapib (100 or
300mg), midazolam exposures (AUC) changed by factors (95% CI) of
1.19 (1.06, 1.33) and 1.44 (1.28, 1.62), respectively. Tolbutamide
exposures (AUC) changed by factors of 0.85 (0.77, 0.94) and 1.06 (0.95,
1.18), respectively. In a phase 2 study, evacetrapib 100mg had minimal
impact on AUC of co-administered simvastatin vs. simvastatin alone
with a ratio of 1.25 (1.03, 1.53) at steady-state, with no differences in
reported hepatic or muscular adverse events.• Evacetrapib minimally impacted exposure
CONCLUSIONS
Taken together, the extent of CYP-mediated DDI with the potential
clinical dose of evacetrapib is weak and clinically important DDIs are
not expected to occur in patients taking concomitant medications.al of Clinical Pharmacology published by
f of The British Pharmacological Society.
vs License, which permits use and distribu-
tions or adaptations are made.
Evacetrapib drug interaction clinical outcomesIntroduction review board (IRB) application. Samples were shipped
to CellzDirect’s facility in Durham, NC, USA for processingProgress has been achieved in reducing cardiovascular
disease morbidity and mortality, largely through
increased use of lipid-lowering therapies such as low-
density lipoprotein-cholesterol (LDL-C)-lowering HMG-CoA
reductase inhibitors (statins) [1–4]. However, therapies
targeting other lipid-related risk factors are needed to ad-
dress the residual risk of cardiovascular events that persists
in many patients. Substantial epidemiological data indicate
high-density lipoprotein-cholesterol (HDL-C) levels are
inversely correlated with cardiovascular disease risk [5–7].
Potent inhibition of cholesteryl ester-transfer protein
(CETP), a plasma glycoprotein that mediates the transfer
of cholesteryl ester from HDL-C to apolipoprotein B-rich
lipoproteins in exchange for triglycerides [8], leads to
decreases of LDL-C and increases of HDL-C concentrations.
Although two previous CETP inhibitors, torcetrapib
and dalcetrapib, were terminated in late-stage clinical
development, there is still considerable interest in this
mechanism as a therapeutic strategy to decrease athero-
genic and increase anti-atherogenic lipoprotein levels.
Evacetrapib, an investigational CETP inhibitor, has not
demonstrated the off-target liabilities associated with
torcetrapib, has been well tolerated and has demon-
strated clinically relevant pharmacodynamic (PD) efﬁ-
cacy in early phase development [9]. In patients with
dyslipidaemia, evacetrapib by itself or in combination
with statins increased HDL-C concentrations and
decreased LDL-C concentrations without producing
signiﬁcant changes in blood pressure, aldosterone,
cortisol or electrolytes.
CETP inhibitors are likely to be utilized in combination
with statins, which are largely metabolised by cytochrome
P450 3A (CYP3A) and are substrates for the hepatic organic
anion transporting polypeptide 1B1 transporter (OATP1B1)
[10]. In addition, the patient population expected to take
CETP inhibitors (i.e., those at high risk for vascular disease)
are likely to be taking multiple concomitant medications.
Consequently, there is a need to understand the beneﬁt-
to-risk proﬁle for evacetrapib, including the potential for
this drug to affect the safety and/or efﬁcacy of other drugs
taken by this patient population. Results from in vitro stud-
ies, predictions, and two clinical studies conducted to as-
sess the potential for inhibitory and inducing drug-drug
interactions (DDI) mediated by evacetrapib are presented.Methods
Reversible inhibition of cytochrome P450 (CYP)
isoforms in human liver microsomes
Experiments were performed at CellzDirect, Inc. (Austin,
TX, USA) utilizing evacetrapib as the lysine salt in human
hepatic microsomes. Each patient whose tissue was used
in this study was fully consented under an institutionalunder protocols approved during the IRB application pro-
cess. Brieﬂy, evacetrapib was incubated at 37°C in 100mM
potassium phosphate buffer (pH7.4) with probe substrates
and β-nicotinamide adenine dinucleotide 2′-phosphate
(NADPH) under linear conditions with respect to protein
content and incubation time. Following the incubation
interval, reactions were stopped, processed for analysis
and analyzed by LC-MS/MS for metabolite formation.
Assay-speciﬁc conditions are summarized in Table 1.
Data analysis The apparent Ki value (dissociation constant
for the enzyme inhibitor complex) was generated by ﬁt of
the appropriate inhibition model using conventional
relationships for inhibition to the data using WinNonlin
Enterprise Edition version 4.1 (Pharsight Corporation,
Mountain View, CA, USA) [11]. To predict the risk of a
clinical DDI, basic models of reversible inhibition were
used. In accordance with the FDA [12] and EMA [13]
guidelines on the investigation of drug interactions, I/Ki
and Iu/Ki values were calculated to relate in vitro to in vivo
risk, where I is the predicted maximum total plasma drug
concentration (Cmax) at the highest recommended dose,
also taking into consideration the unbound fraction, u,
speciﬁc to the EMA guideline. Thus, Iu is the unbound
mean plasma Cmax with the highest recommended dose.
Since the unbound fraction of evacetrapib in human
plasma is very low and prone to uncertainty (<0.1%, data
not presented), a surrogate value of 1% is recommended
for use in the calculation in accordance with European
guidelines. For CYP3A inhibitors, it is also recommended to
take into consideration inhibition of the enzyme in the gut,
where R=1+ [I]gut/Ki and [I]gut=molar dose/250ml in
accordance with FDA guidelines. Similarly, using the EMA
guidance, this equation is [I]/Ki, where [I] is the
maximum dose taken at one occasion/250ml. In
addition to the previously described basic model
equations, the more recent mechanistic static models of
CYP inhibition proposed by Fahmi [14] were also used
in accordance with the FDA and EMA guidances for
drug interaction studies [12, 13]. The mechanistic static
model is described by the following equation:
AUCR ¼ 1= Ag  Bg  Cg
  1 Fg
 þ Fg
  
 1= AhBhChð Þfm þ 1 fmð Þð Þð
where A is the reversible inhibition in either the gut (Ag)
or liver (Ah), B is the time-dependent inhibition in either the
gut (Bg) or liver (Bh), and C is the induction in either the gut
(Cg) or liver (Ch). The equations for A, B, and C are further
characterized in the FDA and EMA guidances and are not
describedwithin the context of thismanuscript [12, 13]. Ad-
ditionally, Fg is described as the fraction of drug available
after intestinal metabolism and fm is the fraction ofBr J Clin Pharmacol / 80:6 / 1389
Table 1
In vitro assay-speciﬁc conditions used in CYP studies in microsomes and hepatocytes













CYP3A4* Midazolam 1-Hydroxy-midazolam 0.5–15 0.025 1–12.5 4





CYP3A4* Testosterone 6β-Hydroxy-testosterone 25–200 0.05 2.5–25 7
CYP3A4‡ Testosterone 6β-Hydroxy-testosterone 200 0.375 x 10
6
cells/0.5 mL
0.1, 1, 10 15
CYP2D6* Bufuralol 1‘Hydroxy-bufuralol 5–100 0.05 4.45–44.5 15
CYP2C19* S-mephenytoin 4’Hydroxy-mephenytoin 10–250 0.1 4–40 30
CYP2C9* Diclofenac 4’Hydroxy-diclofenac 0.5–25 0.05 0.625–10 4
CYP2C8* Paclitaxel 6α-Hydroxy-paclitaxel 1–20 0.075 0.25–2.5 10
CYP2B6* Bupropion Hydroxybupropion 5–1000 0.25 4–40 20
CYP1A2* Phenacetin Paracetamol
(acetaminophen)
15–100 0.1 2.5–25 30
*Reversible inhibition in microsomes. †Time-dependent inhibition in microsomes. ‡Effects in hepatocytes.
E. A. Cannady et al.systemic clearance of the substrate mediated by the CYP
enzyme responsible for its metabolism. The complex equa-
tion described above is the same in both the FDA and EMA
guidances. However, as previously discussed, there are
slight differences in the inputs utilized in each. In the
EMA, but not FDA, guidance, the unbound fraction is taken
into account, with a conservative input of 1% being utilized
for highly protein bound drugs to account for uncertainties
in the estimates. These equations are described in detail in
the regulatory guidances.Time-dependent inhibition of
CYP3A4 in human liver microsomes
In the inactivation assay, 100mM sodium phosphate
buffer (pH 7.4), 1mM ethylenediamine tetraacetic acid
(EDTA), 1mM NADPH and various concentrations of
evacetrapib (lysine salt) were pre-warmed for 3min at
37°C in triplicate. Reactions were initiated with the addi-
tion of human liver microsomes. Then, at multiple time
points, 5μl aliquots were diluted 1/20 into pre-warmed
(37°C) tubes containing the CYP3A4 residual activity mix-
ture. The residual activity assay mixture contained the
CYP3A4 substrate midazolam and NADPH (1mM). Activity
reactions were quenched, samples were processed and
then analyzed for 1-hydroxymidazolam by LC-MS/MS.
Assay-speciﬁc conditions are summarized in Table 1.
Data analysis
Estimates of the following kinetic parameters were deter-
mined according to regulatory guidances and Ring et al.:
kinact (maximal inactivation rate constant), KI (apparent
inactivation constant), CLinact (ratio of kinact/KI) and Kobs1390 / 80:6 / Br J Clin Pharmacol(apparent inactivation rate constant) [12, 13, 15]. Kdeg is
the apparent ﬁrst order degradation rate constant of
the affected enzyme. The basic model equation for
time-dependent inhibition (TDI), in accordance with both
FDA and EMA regulatory guidances [12, 13], utilized was
the following:
R ¼ Kobs þ Kdeg
 
=Kdeg;
where Kobs = kinact[I]/(KI+[I]), noting that two separate
Kdeg values for CYP3A were utilized, one for intestinal
CYP3A and one for hepatic CYP3A. Additionally, in terms
of protein binding, the total [I] was utilized according to
the FDA guidance, whereas the conservative unbound
[I] value of 1% was used for highly protein bound drugs
in accordance with the EMA guidance [12, 13].Effects on CYP3A in human
hepatocyte cultures
Experiments and analyses were performed at CellzDirect,
Inc. (Durham, NC and Austin, TX, USA). Hepatocytes from
three individual donor livers (designated as ‘lots’) were
isolated by a collagenase perfusion method described
by LeCluyse and associates [16, 17] and then plated. Cells
were also resuspended in 60mm dishes for microsomal
preparation required for immunoblotting. Cells were
maintained in media (William’s E Medium, 6.25μgml–1
insulin, 6.25μg l–1 transferrin, 6.25 ngml–1 selenium and
extracellular matrix proteins) for 3 days prior to initiating
treatment with evacetrapib (in triplicate) for up to 72 h.
Cells were also incubated with 0.1% MeOH (vehicle
Evacetrapib drug interaction clinical outcomescontrol) or 10μM rifampicin (CYP3A induction control).
Following incubation, cultures were rinsed twice with
ice-cold Hanks’ Balanced Salt solution (HBSS). HBSS
(0.5ml) containing the CYP3A-selective substrate, testos-
terone, was applied to the cells. Following the appropri-
ate incubation period, supernatants were removed and
frozen until LC-MS/MS analysis for 6β-OH testosterone.
Assay conditions are summarized in Table 1.
mRNA preparation and qRT-PCR determinations
Cells were lyzed and frozen until total RNA was isolated.
Approximately 200 ng of total RNA was reverse tran-
scribed using the Applied Biosystems High Capacity
cDNA Archive Kit according to the manufacturer’s proce-
dures. The resulting cDNA was assayed for relative quan-
tities of CYP3A4 and normalized to the endogenous
control, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), using Applied Biosystems TaqMan® (Life Technol-
ogies, Grand Island, NY, USA).
Western immunoblotting for CYP3A4
Homogenization buffer was added to each dish and cells
were harvested by scraping, pooled by treatment group,
and lysed. Microsomal pellets were prepared by centrifuga-
tion at ~4°C (9000g for 20min followed by further centrifu-
gation of supernatants at 100000g for 60min) and
resuspended in 0.25M sucrose. Samples (20μg) were
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and proteins were transferred electrophore-
tically from the polyacrylamide gels to nitrocellulose
membranes. Membranes were blocked for ≥1h at room
temperature in casein buffer and incubated ≥2h at room
temperature with primary antibodies diluted in casein
buffer. CYP3A4 protein levels were determined with poly-
clonal antibodies. Immunoreactive bands were visualized
on a Fluor-S Chemiluminescence imager with either
enhanced chemiluminescence plus (ECL+; Amersham
Biosciences, Piscataway, NJ, USA) or SuperSignal detection
systems (Thermo Fisher Scientiﬁc, Rockford, IL, USA).Clinical study A: drug–drug
interaction of evacetrapib with
midazolam and tolbutamide in
healthy adult subjects
Study design
A phase 1 single-site, placebo-controlled, investigator
and subject-blinded, parallel, multiple-ascending dose
study evaluated safety, tolerability, pharmacokinetics
(PK) and pharmacodynamics of evacetrapib over four
planned dose levels [18]. Subjects eligible for the study
were between the ages of 18 and 60 years and had a
BMI of 18.5 to 35.0 kgm–2. The Clinical Research Unit
was located in Baltimore, MD, USA and the studyprotocol was reviewed by Chesapeake Research Review,
Inc (Columbia, MD, USA), whichmaintains full accreditation
with the Association for the Accreditation of Hurman Re-
search Protection Programs. Two cohorts incorporated
the evaluation of DDI potential of evacetrapib with two
sensitive CYP substrates using an established drug cocktail
containing midazolam 200μg and tolbutamide 500mg,
which are highly selective probe substrates for CYP3A4
and CYP2C9, respectively [19]. Each cohort of 15 healthy
adults had subjects randomized to receive either
evacetrapib or matched placebo in a ratio of 12 : 3. Subjects
received drug cocktail prior to study drug and on day 1.
Subjects also received repeated daily doses of evacetrapib
100mg or 300mg or placebo for 15days (n=30 subjects).
The pharmacokinetics of midazolam and tolbutamide were
evaluated prior to administration of evacetrapib and on day
15 after evacetrapib had reached steady-state concentra-
tions. To maximize enzyme inhibition prior to the probe
cocktail administration, evacetrapib was administered
~2h before the administration of the probes on day 15.
Plasma probe concentrations were measured immediately
before and by serial collections up to 46 h after giving the
drug cocktail (0.25, 0.5, 1, 2, 4, 6, 8, 12, 22 and 46 h).Bioanalysis
K2EDTA human plasma samples obtained during this study
were analyzed at Bioanalytical Systems, Inc. (BASi; West
Lafayette, IN, USA) for concentrations of evacetrapib using
a validated LC-MS/MS method (data on ﬁle, Eli Lilly and
Company). The dynamic range for the assay was 1 to
1000ngml–1. Samples above the limit of quantiﬁcation were
diluted and re-analyzed to yield results within the calibrated
range. The inter-assay accuracy (% relative error) during val-
idation ranged from 6.0% to 6.2%. The inter-assay preci-
sion (% relative standard deviation) during validation
ranged from 2.1% to 6.4%. Plasma samples were analyzed
for midazolam and 1′-hydroxymidazolam using the vali-
dated LC-MS/MSmethod at Advion BioServices, Inc. (Advion;
Ithaca, NY, USA). The dynamic range for both analytes was
0.01 to 10ngml–1. The inter-and intra-assay accuracy ranged
from 0.56% to 20.0% for midazolam, and from 2.90% to
11.7% for 1′-hydroxymidazolam. The inter- and intra-assay
precision was ≤9.64% for midazolam and ≤9.71% for
1′-hydroxymidazolam. Plasma samples were also analyzed
for tolbutamide using a validated LC-MS/MS method at
Covance Laboratories Inc. (Madison, WI, USA). The dynamic
range of the assay was 5 to 2000ngml–1. Samples above
the limit of quantiﬁcation were diluted and re-analyzed to
yield results within the calibrated range. The intra-assay
accuracy for tolbutamide ranged from 94.7% to 106% and
the intra-assay precision ranged from 6.2% to 8.3%.
Pharmacokinetic analysis
Pharmacokinetic parameter estimates for evacetrapib,
midazolam, 1′-hydroxymidazolam and tolbutamide wereBr J Clin Pharmacol / 80:6 / 1391
E. A. Cannady et al.calculated by standard non-compartmental methods of
analysis. The primary parameters were maximum con-
centration (Cmax) and area under the curve (AUC) of
evacetrapib, midazolam, 1′-hydroxymidazolam and tol-
butamide. A mixed model repeated measures (MMRM)
analysis was conducted to estimate mean AUC(0,∞) and
Cmax of midazolam and tolbutamide in the presence
and absence of evacetrapib. The MMRM model used
log-transformed AUC(0,∞) and Cmax as the response
and included log-transformed dose, treatment (with or
without evacetrapib) and log-transformed dose by
treatment interaction as ﬁxed effects, and subject as a
random effect. Least squares geometric mean ratios
and 95% conﬁdence intervals (CI) were calculated for
the inference of exposure ratios of midazolam and
tolbutamide in the presence and absence of evacetrapib.Clinical study B: drug–drug




A randomized, double-blind, double-dummy, parallel
group, placebo- and active-controlled, multi-site phase
2 efﬁcacy and safety study of evacetrapib was conducted
in adult patients (≥18 years; n=398) with hypercholester-
olaemia or low HDL-C [9]. The trial was designed by the
Cleveland Clinic Coordinating Center for Clinical Re-
search (IRB approval # QUI1-09–464) in collaboration
with the sponsor and conducted at 70 sites internation-
ally. Patients were randomized to 30, 100 or 500mg
evacetrapib daily as monotherapy, 40mg simvastatin as
monotherapy or in combination with 100mg evacetrapib,
or placebo alone. Treatment duration was 12weeks. To
evaluate CYP-mediated drug interactions, evacetrapib and
simvastatin pharmacokinetic sampling occurred at weeks
2, 4, 8 and 12 (visits 4, 5, 6 and 7). Sampling at each visit
consisted of a pre-dose and a post-dose blood draw during
the treatment to allow for population PK analysis with a
maximum allowable window of 4days. A single sample
was also drawn at the follow-up visit (visit 8, week 16–18)
or after early discontinuation.Bioanalysis
Plasma samples were analyzed for evacetrapib as described
above. Plasma samples were also analyzed for simvastatin
(parent= simvastatin lactone) and its metabolite (simva-
statin acid) at Advion BioServices, Inc. (Advion; Ithaca,
NY, USA) utilizing a validated LC-MS/MS assay. For simva-
statin and its metabolite, the detection range was 0.10 to
30ngml–1 for both analytes. The inter-assay accuracy
ranged from 1.0% to 13.2% for simvastatin and from
8.0% to 8.5% for simvastatin acid. The inter-assay
1392 / 80:6 / Br J Clin Pharmacolprecision was ≤7.9% for simvastatin and ≤8.9% for simva-
statin acid. For all analytes, when samples had concentra-
tions above the limit of quantitation, samples were
diluted to yield results within the calibrated range.
Pharmacokinetic analysis
Analyses were performed using a non-linear mixed effect
modelling approach as implemented in NONMEM version
7. The post hoc Bayesian estimates of CL/F from the popu-
lation PK models were used to calculate the ratio of the
steady-state AUC of the statin when co-administered with
evacetrapib relative to when the statin was administered
alone, resulting in a mean ratio and the corresponding
95% CI. The geometric mean ratio of the plasma concen-
tration of simvastatin to the corresponding metabolite at
trough and Cmax was also calculated for the statin alone
and when co-administered with evacetrapib.Additional assessments for both
clinical drug–drug interaction
studies
Safety assessments in the drug–drug interaction
studies
Safety measurements included recording adverse events
and evaluation of clinical laboratory data in both of the
clinical studies.
Ethical review of clinical studies
Ethical Review Boards for the two clinical studies ap-
proved their respective protocols. Healthy subjects and
patients in the clinical studies provided written informed
consent prior to participation in study procedures.Results
Reversible inhibition of CYP isoforms in human
liver microsomes
Based on in vitro inhibition of the metabolism of form-
selective substrates, evacetrapib inhibited several major
CYP isoforms (CYPs 3A4, 2C19, 2C9, 2D6, 2C8, 2B6 and
1A2). Inhibition constant (Ki) values for evacetrapib
ranged from 0.57μM (CYP2C9) to 7.6μM (CYP2C19) and
are presented in Table 2. To predict the risk of a clinical
DDI, I/Ki values were calculated to relate in vitro to
in vivo risk, where I is the predicted maximum total drug
concentration (Cmax) value (1.9μM) for the phase 3 dose
of 130mg. The I/Ki values ranged from 0.25 (CYP2C19)
to 3.30 (CYP2C9), also shown in Table 2.
In accordance with regulatory agency guidelines, the
FDA and EMA basic models were applied as a ﬁrst line as-
sessment of DDI potential [12, 13]. Using the FDA guid-
ance equation, the resulting R value was 2.57 or 4.30 for
Table 2
in vitro inhibition constant (Ki, I/Ki, and Iu/Ki) values for evacetrapib
Cytochrome P450 (Form-selective catalytic activity) Model best describing the data Apparent Ki (μM) †I/Ki ‡Iu/Ki
CYP3A4 (Midazolam 1′-hydroxylation) Non-competitive 1.2 ± 0.15 1.57 0.02
CYP3A4 (Testosterone 6β-hydroxylation) Competitive 3.6 ± 0.9 0.52 0.005
CYP2D6 (Bufuralol 1′-hydroxylation) Competitive 2.1 ± 0.5 0.89 0.009
CYP2C19 (S)-(Mephenytoin 4′-hydroxylation) Mixed competitive/non-competitive 7.6 ± 1.1 α = 4.5 ± 1.2 0.25 0.003
CYP2C9 (Diclofenac 4′-hydroxylation) Competitive 0.57 ± 0.05 3.30 0.03
CYP2C8 (Paclitaxel 6α-hydroxylation) Non-competitive 1.3 ± 0.1 1.45 0.01
CYP2B6 (Bupropion hydroxylation) Non-competitive 6.3 ± 1.0 0.30 0.003
CYP1A2 (Phenacetin metabolism to paracetamol (acetaminophen)) Competitive 7.1 ± 2.1 0.26 0.003
†I = predicted Cmax of 1.879 μM at 130 mg dose. ‡unbound fraction = 1% in accordance with EMA guidance
13
Evacetrapib drug interaction clinical outcomesCYP3A or CYP2C9, respectively, also shown in Table 3.
Using the similar EMA equation, with different inputs de-
scribed previously and an Iu value of 0.019μM for the pre-
dicted phase 3 dose of 130mg evacetrapib the
Iu/Ki = 0.02 for CYP3A and Iu/Ki = 0.03 for CYP2C9 (Table
3), with the lowest Iu/Ki value being 0.003 for CYP2C19
(Table 2). A clinical interaction study with a sensitive
probe substrate is recommended if the R value >1.1,
using the FDA basic model, or if the ratio of Iu/Ki ≥0.02
using the EMA basic model. In both instances, the clinical
DDI potential could not be excluded for evacetrapib and
clinical studies were warranted.
Additionally, the potential for inhibition of CYP3A in
the gastrointestinal tract by evacetrapib similarly could
not be excluded. A clinical drug interaction study with a
sensitive probe substrate is recommended when the R
value ≥11. For a 130mg maximum recommended dose
of evacetrapib, the R value was 679.46 (Table 3).
In a second line assessment, the mechanistic static
models recommended in the FDA and EMA regulatory
guidances [12, 13] were used to predict evacetrapib in-
teractions with CYP3A and CYP2C9. The evacetrapib
AUC ratio for CYP3A was predicted to be 1.76X or
2.95X using the mechanistic static models utilized by
the FDA and EMA, respectively. The differences in the
predicted AUC ratios derived by each method are at-
tributed to the different inputs used in the respective
equations as described previously. Nonetheless, since
the AUC ratio falls outside of the 0.8 to 1.25 range,
the modelled values are considered a positive effect
regardless of which model is used, and clinical evalua-
tion is warranted (Table 3). The FDA mechanistic static
model predicted the evacetrapib AUC ratio for CYP2C9
to be 1.0, whereas using the more conservative
unbound fraction term in the EMA mechanistic static
model predicted slightly different AUC ratios of 1.13X
or 1.12X, using either warfarin or tolbutamide as sub-
strate, respectively (Table 3).Time-dependent inhibition of CYP3A4 in human
liver microsomes
Time-dependent inhibition (TDI) of CYP3A4-mediated mid-
azolam 1-hydroxylation was observed for evacetrapib,
yielding a kinact value of 0.144min
–1 and KI value of
34.0μM. The corresponding inactivation clearance (CLinact)
was 4.2min1mM1. Using the FDA and EMA TDI basic
models, the predicted R values were 24.4 and 1.25, respec-
tively. The difference in predicted R values is attributed to
the unbound fraction inputs into the models, as previously
described. However, predictions based on both FDA and
EMA models warranted further clinical investigation
(Table 3).Effects on CYP3A in human hepatocytes
Primary cultures of fresh human hepatocytes responded to
the positive control, rifampicin, appropriately, and the assay
was deemed acceptable. Figure 1 shows the time-course of
effects of evacetrapib on CYP3A4 mRNA (Figure 1A) and
CYP3A-mediated testosterone 6β-hydroxylation activity
(Figure 1B). The effects of evacetrapib were
concentration- and time-dependent. There was little effect
of 0.1μM evacetrapib on mRNA and activity. However, in
hepatocyte cultures treated with 1 and 10μM evacetrapib,
CYP3A4 mRNA levels increased by 8h and remained ele-
vated at 72h. The average effect (treatment/vehicle) of
10μM evacetrapib in the three lots at 72h was 11.5 (51%
of rifampicin, data on ﬁle). Decreases in CYP3A-mediated
activity were observed for 1 and 10μM evacetrapib over
the shorter treatment periods (2, 4 and 8h). By 72h, how-
ever, CYP3A-mediated activity had returned to baseline
(1μM) or had rebounded to approximately 50% of baseline
(10μM) (Figure 1). Representative semi-quantitative immu-
noblots showing CYP3A4 protein levels (Figure 2) show
evacetrapib concentration-related decreases in CYP3A4
protein at 8h and slight concentration-related increases
in CYP3A4 protein at 72h.Br J Clin Pharmacol / 80:6 / 1393
Table 3
Predictions of clinically relevant drug–drug interactions using 130 mg
dose of evacetrapib based on reversible basic, TDI basic and mechanis-







- FDA*,†† R = 2.57 Yes R = 4.30 Yes
- EMA†,§§ Iu/Ki = 0.02 Yes¶¶ Iu/Ki = 0.03 Yes
Reversible basic - Gut
- FDA‡ R = 679.46 Yes NA NA
- EMA‡ R = 679.46 Yes NA NA
TDI/MBI basic
- FDA§,† R = 24.4 Yes NA NA
- EMA¶,§§ R = 1.25 Yes¶¶ NA NA
Mechanistic static
- FDA**,‡‡ AUCR =1.76 Yes AUCR =1.0 No






*Clinical study warranted when R ≥ 1.1. †Clinical study warranted when Iu/
Ki ≥ 0.02. ‡Clinical study warranted when R ≥ 11. §Clinical study warranted
when R ≥ 1.1. ¶Clinical study warranted when R ≥ 1.25. **Clinical study war-
ranted when AUCR >1.25. ††Total drug concentrations used in calculation
‡‡Unbound drug concentrations used in calculation. §§Conservative estimate of
unbound drug concentrations (1%) used in calculation for highly protein bound
drugs. ¶¶Using full precision, these values fell slightly below the threshold to
conduct a clinical study. However, values were rounded to account for inaccura-
cies, leading to the recommendation to conduct a clinical study.
NA = not applicable. TDI = time-dependent inhibition. MBI = mechanism-based
inhibition.
E. A. Cannady et al.Clinical study A: Drug–drug interaction study of
evacetrapib with midazolam and tolbutamide in
healthy human subjects
Pharmacokinetics of midazolam and tolbutamide Adminis-
tration of evacetrapib slightly increased midazolam
exposure, whereas the effect on tolbutamide exposure
was minimal (Figure 3A and B). Geometric mean ratios
of plasma midazolam AUC from time 0 to inﬁnity (AUC
(0,∞)) in the presence on day 1 and absence on day 15
of evacetrapib were 1.19 (95% CI 1.06, 1.33) (P=0.004)
and 1.44 (95% CI 1.28, 1.62) (P< 0.001) for evacetrapib
100mg and 300mg, respectively (Table 4). Geometric
mean ratios of Cmax were 1.29 (95% CI 1.07, 1.54)
(P=0.009) and 1.26 (95% CI 1.04, 1.52) (P=0.020),
respectively. The exposures of the midazolam metabolite,
1′-hydroxymidazolam, were not as strongly affected by
evacetrapib as was midazolam itself. The AUC and Cmax
of 1′-hydroxymidazolam were not signiﬁcantly affected
by 14 daily doses of 100mg of evacetrapib. Following
14 daily doses of 300mg of evacetrapib, the AUC(0,∞)
of 1′-hydroxymidazolam increased by a factor of 1.18.
The Cmax of 1′-hydroxymidazolam was not signiﬁcantly
affected by 300mg of evacetrapib (Table 4). The
geometric mean ratios of plasma tolbutamide AUC(0,∞)1394 / 80:6 / Br J Clin Pharmacolin the presence and absence of evacetrapib were 0.85
(95% CI 0.77, 0.94) (P=0.002) and 1.06 (95% CI 0.95,
1.18) (P=0.262) following 14 daily doses of 100mg or
300mg, respectively; for Cmax the ratios were 1.02 (95%
CI 0.92, 1.14) (P=0.675) and 0.99 (95% CI 0.89, 1.12)
(P=0.917), respectively.
Adverse events Among cohorts that received DDI probes,
one subject receiving 100mg evacetrapib showed an
elevation in ALT and AST. The elevation in hepatic
transaminases in this subject occurred after the ﬁrst
administration of probe substrates and was less than
three times the upper limit of normal range. Total
bilirubin was in the normal range.
Clinical study B: Drug–drug interaction study of
evacetrapib with simvastatin in dyslipidaemic
patients
Pharmacokinetics of simvastatin Co-administration of
evacetrapib with simvastatin resulted in a mean AUC
(0,τss) ratio of 1.25 (95% CI 1.03, 1.53), relative to
administering the statin alone (Table 5). The effect of
evacetrapib on simvastatin exposure was statistically
signiﬁcant (P< 0.025). The impact of evacetrapib on the
geometric mean ratios between parent (simvastatin
lactone) and metabolite (simvastatin acid) plasma
concentrations at trough and Cmax of simvastatin was
minimal. At trough, the parent to metabolite ratios were
1.09 in both the absence and presence of evacetrapib,
resulting in an overall ratio (statin+evacetrapib/statin
alone) of 1.00. At Cmax, the parent to metabolite ratios were
4.15 and 4.77 in the absence and presence of evacetrapib,
respectively, resulting in an overall ratio of 1.15.
Adverse events In patients receiving simvastatin alone or
in combination with evacetrapib, no clinically important
differences were found regarding clinical laboratories or
treatment emergent adverse events.Discussion
Evacetrapib is a reversible inhibitor of multiple cyto-
chromes P450 (3A4, 2D6, 2C19, 2C9, 2C8, 1A2) in vitro. A
risk assessment using the basic and conservative I/Ki
methods was performed and suggested that evacetrapib
had the potential to inhibit the metabolism of co-
administered drugs metabolized by CYP3A and CYP2C9
because estimated Iu/Ki ratios exceeded the EMA-
recommended threshold of 0.02 [13]. Based on the more
recent FDA and EMA guidances, the reversible basic
models of inhibition predicted clinically relevant DDI
for both CYP3A and CYP2C9, while clinically relevant
inhibition of CYP3A, but not CYP2C9, was predicted using
the mechanistic static models [12, 13]. Furthermore,
CYP3A4-relative mRNA content 
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Time course (2–72 h) of mean effects (treatment/vehicle) of evacetrapib
on CYP3A4 relative mRNA content (A) and CYP3A-mediated testoster-
one 6β-hydroxylation (B) on multiple lots (n= 3) of primary human hepato-
cytes. Error bars indicate standard deviation at 8 and 72 h timepoints. At
2 and 4 h timepoints, error bars are not shown because only two lots
were incubated. Treatment/vehicle = 1 indicates no effect. ( 0.1μM,
1μM, 10 μM)
Evacetrapib drug interaction clinical outcomesinhibition of CYP3A in the gut by evacetrapib was also
predicted.
In vitro, evacetrapib was also identiﬁed as a time-
dependent inhibitor of CYP3A4 activity in microsomes
and cultured hepatocytes. In the hepatocyte experi-
ments, we investigated the time course of the effects of
evacetrapib on CYP3A4 mRNA, total protein and activity
in addition to the standard 48–72h terminal time point.
The effects of evacetrapib were dependent on the CYP3A
end point being measured, treatment time, and
evacetrapib concentration. At concentrations similar to
those achieved in the clinic (1.9μM for the phase 3 dose
of 130mg), mRNA levels increased within 8h while inhibi-
tion of CYP3A activity in hepatocyte preparations appeared
to manifest over short treatment intervals (2–8h). At 72h,
the inhibitory effects on activity were no longer evident inpreparations treated with 1μM evacetrapib, but continued
to dominate in preparations treated with 10μM evacetrapib
even though protein levels had rebounded. It was con-
cluded that CYP3A4 was likely inactivated during the
in vitrometabolism of evacetrapib, with the inactivated en-
zyme efﬁciently being removed from the pool of CYP3A4
recognizable by the immunoblotting antibody. Clinically
relevant inhibition of CYP3A could not be ruled out, based
on predictions utilizing the FDA and EMA basic models for
time-dependent/mechanism-based inhibition.
Overall, the combined data from the in vitro studies of
evacetrapib in liver microsomes and hepatocyte prepara-
tions suggest a complex interplay of reversible inhibition,
time-dependent inhibition, induction of CYP3A and
concentration-dependent effects. Thus, a clinical CYP3A
DDI study was warranted and midazolam was chosen as
the sensitive substrate to probe this potential interaction.
The in vitro risk assessment also suggested that evacetrapib
had the potential to inhibit the metabolism of co-
administered drugs metabolized by CYP2C9, although the
more recent mechanistic static model predictions sug-
gested that there would not be a clinically signiﬁcant inter-
action. However, a conservative approach was taken and
the clinical DDI study was conducted utilizing tolbutamide
as the CYP2C9 probe substrate.
In the phase 1 study in healthy subjects, which uti-
lized midazolam and tolbutamide probes, the AUC ratio
data at steady-state indicated that evacetrapib is a weak
inhibitor of CYP3A but had no statistically signiﬁcant
effect on CYP2C9-mediated metabolism. These conclu-
sions are drawn based on the FDA and EMA classiﬁcation
criteria whereby weak inhibitors result in ≥1.25-fold in-
crease to <2-fold increase in AUC values. Our data indi-
cate that a weak interaction with CYP3A4 occurred at
both 100 and 300mg doses of evacetrapib, whereas the
AUC ratios for CYP2C9 ranged from 0.85 to 1.06, indicat-
ing minimal interaction with CYP2C9. Thus, these studies
suggested a low risk of clinically relevant DDIs between
evacetrapib and CYP3A4 and CYP2C9 substrates that
may be taken as concomitant medications. Furthermore,
since the most potent observed in vitro Ki value was asso-
ciated with CYP2C9, and given that the DDI study indi-
cated that evacetrapib is unlikely to cause clinically
signiﬁcant interactions requiring dose adjustments of
co-medications metabolized by CYP3A4 or CYP2C9, it
can be concluded that clinically signiﬁcant inhibition of
the other CYP enzymes with less potent Ki values (up to
7.6μM for CYP2C19) is unlikely.
The potential for CYP3A-mediated DDIs was also in-
vestigated in the anticipated dyslipidaemic patient pop-
ulation for evacetrapib, which includes patients with
high-risk vascular disease taking concomitant therapies
such as statins. The subsequent phase 2 study in patients
demonstrated that evacetrapib had minimal impact on
the steady-state AUC of simvastatin. Co-administration
of simvastatin with evacetrapib resulted in a mean statinBr J Clin Pharmacol / 80:6 / 1395
AB
Figure 2
Representative Western immunoblots following treatment with
evacetrapib and controls. Panel A: 8 h; Panel B: 72 h
E. A. Cannady et al.AUC ratio of 1.25, relative to administering the statin
alone. Evacetrapib also had only a very limited effect on
the parent :metabolite concentration ratio.Time (h)
































































Plasmamidazolam (Panel A, Midazolamonly (Day4), Midazolam
+ 100 mg evacetrapib (Day 15), Midazolam + 300 mg evacetrapib
(Day 15)) and tolbutamide (Panel B, Tolbutamide only (Day 4),
Tolbutamide + 100 mg evacetrapib (Day 15), Tolbutamide
+ 300 mg evacetrapib (Day 15)) concentrations over time in Phase 1
study
1396 / 80:6 / Br J Clin PharmacolPhase 2 safety data showed that 12-week therapy
with daily doses of evacetrapib up to 500mg as mono-
therapy or evacetrapib 100mg in combination with sim-
vastatin was well tolerated. No evidence of any adverse
effect of evacetrapib on hepatic or muscle safety
emerged during the active treatment phase. In their anal-
ysis of the phase 2 study database, Nicholls et al. reported
that evacetrapib was well tolerated [9]. Although their
analysis was underpowered to rule out uncommon ad-
verse effects, these investigators did not detect any clin-
ically signiﬁcant side effects or laboratory abnormalities
related to liver, kidney or muscle toxicity.
Although our in vitro data suggested that evacetrapib
has the potential to affect multiple CYPs, several factors
may account for the mild interactions observed in clinical
studies. First, when one considers the high plasma pro-
tein binding of evacetrapib (≥99.9%) [20] and low un-
bound fraction in the circulation, the likelihood of a
clinically signiﬁcant DDI is reduced. Secondly, the
in vitro data suggested that evacetrapib is potentially
only a weak time-dependent inhibitor of CYP3A4
in vivo. Evacetrapib is also an inducer of CYP3A and thus
possesses potentially offsetting inductive and inhibitory
properties. Although evacetrapib showed the potential
to induce CYP3A in vitro, the potential to produce clini-
cally relevant in vivo induction of CYP3A catalytic activity
over the concentration range examined was low due to
the apparent dual inducing and inhibiting effects of
evacetrapib on CYP3A mRNA and enzyme activity. Such
normalization appears to translate into a low risk of clin-
ically meaningful DDIs. Other examples of marketed
drugs thought to have similar mechanisms of dual inhibi-
tion and induction of CYP3A observed in vitro, which pre-
sumably offsets the clinical signiﬁcance, are tadalaﬁl [15]
and ritonavir [21].
In conclusion, the initial in vitro data predicted that
evacetrapib could be an inhibitor of multiple CYP en-
zymes and could be an inducer of CYP3A. The CYP3A4 in-
hibition potential was further supported by using
updated models to predict the likelihood of DDI. How-
ever, well designed clinical studies with probe substrates
selected on the basis of in vitro risk assessment tools and
modelling approaches suggested that there was no
evidence of any clinically relevant DDI with evacetrapib
as the perpetrator drug. Furthermore, there was no
evidence of adverse effects of evacetrapib on liver or
muscle safety when given as monotherapy or in com-
bination with simvastatin, nor were there any statisti-
cally or clinically signiﬁcant effects of evacetrapib on
mean change from baseline in liver or muscle-related
laboratory parameters. Evacetrapib minimally impacted
exposure of simvastatin, which suggests that dose adjust-
ments of this concomitant medication, or other CYP3A sub-
strates, will not be warranted and that interactions with
drugs cleared through this pathway are unlikely. Further-
more, atorvastatin was included in the phase 2 study, as a
Table 4
AUC(0,∞) and Cmax of midazolam, 1′-hydroxymidazolam and tolbutamide before and after 14 daily doses of 100 mg or 300mg evacetrapib in the phase
1 study




h) 100 3.1 (2.5, 4.0) 2.6 (2.1, 3.4) 1.19 (1.06, 1.33) 0.004
300 3.1 (2.4, 4.0) 2.3 (1.8, 2.9) 1.44 (1.28, 1.62) <0.001
Cmax (ng ml
–1
) 100 1.3 (1.1, 1.6) 1.0 (0.9, 1.2) 1.29 (1.07, 1.54) 0.009




h) 100 1.0 (0.9, 1.1) 0.9 (0.7, 1.0) 1.11 (0.99, 1.26) 0.07
300 0.8 (0.6, 1.0) 0.7 (0.6, 0.8) 1.18 (1.04, 1.33) 0.01
Cmax (ng ml
–1
) 100 0.4 (0.3, 0.5) 0.3 (0.3, 0.4) 1.16 (0.94, 1.43) 0.16
300 0.3 (0.2, 0.3) 0.3 (0.2, 0.3) 0.96 (0.78, 1.20) 0.73
Tolbutamide
AUC(0,∞) (μg ml–1 h) 100 581 (466, 725) 678 (548, 839) 0.85 (0.77, 0.94) 0.002
300 559 (492, 635) 579 (460, 728) 1.06 (0.95, 1.18) 0.26
Cmax (μg ml
–1
) 100 42 (38, 47) 41 (37, 46) 1.02 (0.92, 1.14) 0.68
300 43 (39, 48) 44 (38, 50) 0.99 (0.89, 1.12) 0.92
Note: except for doses and P values, the numbers presented in each cell are the geometric mean (95%CI). AUC(0,∞), plasma area under the concentration vs. time curve from time
0 to inﬁnity; Cmax, maximum plasma concentration.
Table 5
AUCτss and AUCτss ratio of evacetrapib plus simvastatin vs. simvastatin





AUC(0,τss) ratio (evacetrapib and
statin/statin alone) (95% CI)
Evacetrapib/
Simvastatin




AUC(0,τss), area under the concentration vs. time curve (dosing interval, steady-
state), calculated using the statin dose and post-hoc individual estimate of statin
clearance from the population PK analysis (Dose/CL). *P < 0.025 based on two-
sided hypothesis test at the 0.025 level (95% CI).
Evacetrapib drug interaction clinical outcomescomparator drug, in which evacetrapib also had minimal ef-
fect on its exposure (data not shown). Overall, the present
studies support the conclusion that the risk of clinically rele-
vant CYP-mediated DDIs is low with evacetrapib at the likely
prescribed dose level in the intended patient population.Competing Interests
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